Author | Hugo E. Velázquez, MD


Diffuse Hepatic Infiltration by Metastatic Melanoma

July 16, 2019

ByHugo E. Velázquez, MD|Francisco J. Castro-Alonso, MD|Christianne Bourlon, MD, MS|Alejandro Gabutti, MD|Cecilia Gallegos, MD|María T. Bourlon, MD, MSc

Melanoma of the skin is the 19th most common malignant neoplasm worldwide, with 287,723 new cases estimated for 2018 and metastatic melanoma accounting for 4% of all new cases. In recent years, the prognosis of this stage has undergone a dramatic transformation with the advent of immunotherapy and BRAF/MEK targeted therapy.

Is This Patient With Metastatic Bladder Cancer a Candidate for Second-Line Immunotherapy Treatment?

February 15, 2018

ByMaría T. Bourlon, MD, MSc|Hugo E. Velázquez, MD|Rodrigo Luna-Santiago, MD|Sara Vázquez-Manjarrez, MD|Christianne Bourlon, MD, MHSc

A 67-year-old man, a former smoker, presented with gross hematuria. A CT urogram showed a bladder tumor in the anterior wall and multiple enlarged retroperitoneal lymph nodes. Two vertebral metastases were seen on a bone scan. He underwent a transurethral resection of the bladder, and the pathology report revealed muscle-invasive urothelial carcinoma.